Kathleen Rickard, a respiratory medicine expert, has joined Verona Pharma Plc as chief medical officer to help the company bring its lead product for chronic obstructive pulmonary disease into Phase 3. Dr Rickard has held executive positions at Circassia Pharmaceuticals Plc and at the medical technology company Aerocrine AB, as well as managed clinical development and medical affairs at GlaxoSmithKline’s respiratory medicines development centre.
Dr Rickard will be joined on the Verona executive team by Tara Rheault who becomes head of global project management. Dr Rheault is also a veteran of GSK.
Drs Rickard and Rheault will be based in the US.
Verona Pharma announced the appointments on 3 January 2019.
Copyright 2019 Evernow Publishing Ltd